Robert Ahlgren is listed as a director on 2 SEC Form D filings by 1 issuer between Apr 2024 and Jun 2025: Immunomic Therapeutics, Inc. (Rockville, MD — biotechnology — 2024–2025; $77.7M reported sold to 60 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Dong-Gun Kim (2 shared filings), James Wishart (2 shared filings), Ki-Hong Ahn (2 shared filings), Matthew Chang (2 shared filings), Steve Park (2 shared filings) and 4 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 3 bankruptcy cases matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 2 public filings for Robert Ahlgren and found 4 differences, 1 worth asking the sponsor about: Form D filed 71 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.